2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Clinical Procedures, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pregnant, Young Adult
PAPER

3811 Clinically relevant safety characterization of higher initial dose and accelerated titration (HIDAT) of ropeginterferon alfa-2b in essential thrombocythemia: A pooled safety analysis of the SURPASS-ET and EXCEED-ET trials

Tsewang Tashi, MD, Brandi N Reeves, MD2, Lei Zhang, MD3, Harinder Gill, MBBS, MD4, Keita Kirito, MD5, Kohshi Ohishi, MD6, Norio Komatsu, MD, PhD7, Shuichi Shirane, MD, PhD8, Jie Jin, MD9, Zhijian Xiao10, Xuelan Zuo11, Firas El Chaer, MD12, Lynda Foltz, MD13, Pankit Vachhani, MD14, Sung-Eun Lee, MD, PhD15, Lee-Yung Shih, MD16, Shinya Imada, MD, PhD17, Albert Qin, MD PhD18, Lucia Masarova, MD19
1 University of Utah, Salt Lake City, United States
2 The University of North Carolina at Chapel Hill, Chapel Hill, United States
3 Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
4 LKS Faculty of Hong Kong, Hong Kong, Hong Kong
5 University of Yamanashi, Yamanashi, Japan
6 Mie University Hospital, Mie, Japan
7 Juntendo University Graduate School of Medicine, Tokyo, Japan, Juntendo University School of Medicine, Tokyo, United States, PharmaEssentia Japan KK, Tokyo, Japan
8 Juntendo University Graduate School of Medicine, Tokyo, Japan, Juntendo University School of Medicine, Tokyo, United States
9 Zhejiang University School of Medicine, Hangzhou, China
10 Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
11 Wuhan University, Wuhan, China
12 Florida International University, Miami, United States, Herbert Wertheim Cancer Institute, Miami, United States
13 University of British Columbia, Vancouver, Canada
14 The University of Alabama, Birmingham, United States
15 The Catholic University of Korea, Seoul, Korea, Rep. of South
16 Chang Gung University, Taoyuan, Taiwan
17 PharmaEssentia Corporation, Burlington, United States
18 PharmaEssentia Corporation, Taipei, Taiwan
19 The University of Texas MD Anderson Cancer Center, Houston, United States

Background: Ropeginterferon alfa-2b is a mono-pegylated interferon-α approved for adults with polycythemia vera, with emerging clinical evidence for essential thrombocythemia (ET). Ropeginterferon alfa-2b is currently labeled for slow uptitration to a clinically effective dose over 16 weeks; however, a more rapid titration to a maximal dose over 4 weeks has been tested in 2 recent ET studies (Higher Initial Dose and Accelerated Titration [HIDAT], 250-350-500 µg Q2-weekly). SURPASS-ET is a global, phase 3, randomized study of ropeginterferon alfa-2b versus anagrelide, with approximately 95% enrollees from Asia. EXCEED-ET is a North American, single-arm, phase 2b study of ropeginterferon alfa-2b. Both studies demonstrated favorable hematologic and molecular responses with a manageable safety profile. However, further investigation is needed to better characterize the clinical relevance of the HIDAT safety profile, including the timing, reversibility, and management of adverse events (AE). We performed a prespecified pooled safety analysis evaluating tolerability, temporal AE patterns, and subgroup consistency across 182 treated patients.

Methods: All patients treated with ropeginterferon alfa-2b from SURPASS-ET (n=91) and EXCEED-ET (n=91) were included. AEs were graded according to Common Terminology Criteria for Adverse Events V5.0. Safety analyses included treatment exposures, dose modifications, AE severity, time to first AE, longitudinal AE patterns, AE recurrence following dose rechallenge, and prespecified subgroup analyses stratified by sex and age (<65 vs ≥65 years).

Results: Among the 182 patients (median age 60 years, 57.1% female; 35.7% aged >65 years), median treatment duration was 11.9 (SURPASS-ET) and 13.3 months (EXCEED-ET). Target ropeginterferon alfa-2b dose (500 µg) was achieved in both studies by month 3; subsequent dose reductions were more frequent in EXCEED-ET than SURPASS-ET (70.3% vs 45.1%). Importantly, permanent treatment discontinuation was rare (SURPASS-ET, 0%; EXCEED-ET, 2.2%; overall, 1.1%), and study withdrawal rates remained similarly low (SURPASS-ET, 0%; EXCEED-ET, 1.1%; overall, 0.5%).

Nearly all patients (99.5% overall) experienced ≥1 AE (SURPASS-ET, 98.9%; EXCEED-ET, 100%), mostly grades 1 and 2. Grade 3 and 4 AEs occurred in 26.9% (20.9%, 33.0%), and 1.6% of patients (2.2%, 1.1%), respectively, and no grade 5 events were reported. Treatment-emergent serious AEs (SAEs) occurred in 12.6% of patients (SURPASS-ET, 14.3%; EXCEED-ET, 11.0%), with treatment-related SAEs in 3.8% of patients (2.2%, 5.5%).

AE frequency peaked during the early treatment phase and declined with prolonged therapy: the cumulative overall AE rate per 100 patient-weeks was 60.1 at weeks 0-4, 43.1 at weeks 5-8, and 32.1 at weeks 9-12; rates ranged from 23.5 to 27.2 at weeks 13-20 and from 9.9 to 19.7 at weeks ≥21. Three clinically distinct temporal patterns of AE onset were identified: (1) early onset (<4 weeks; flu-like syndrome), (2) mid-treatment onset (4-16 weeks; fatigue, headache, pruritus, liver enzyme elevations, and neutrophil decrease), and (3) late onset (>16 weeks; depression, alopecia, eye disorders, anemia, and thrombocytopenia). Exposure-adjusted incidence rates for representative intermediate-onset AEs, including fatigue, AST elevation, and pruritus, were low, at 1.22, 1.97, and 0.58 events per 100 patient-weeks, respectively.

AE recurrence after dose rechallenge was infrequent (12/182 patients; 6.6%), predominantly ALT increase (3.9%), AST increase (2.2%), and neutrophil decrease (1.7%). Depression occurred in 5.5% of all patients (grade ≥3: 0.5%). The overall safety profile was comparable between male and female patients. In contrast, patients aged ≥65 years experienced significantly higher rates of grade ≥3 AEs compared to <65 years (38.5% vs 20.5%; P=0.009), SAEs (24.6% vs 6.0%; P=0.0006), and AE-related withdrawal (15.4% vs 4.3%; P=0.015), highlighting age as an important safety modifier.

Conclusions: The ropeginterferon alfa-2b HIDAT regimen demonstrated a predictable and manageable safety profile in patients with ET, characterized by: dose flexibility rather than discontinuation; front-loaded overall AEs that declined with prolonged therapy; 3 clinically actionable AE patterns with low recurrence after dose rechallenge; and a significantly higher SAE burden among patients aged ≥65 years, supporting the need for individualized management in older patients.

Tsewang Tashi, MD: Blueprint Medicines Corporation, a wholly owned subsidiary of Sanofi - Honoraria; Blueprint Medicines Corporation, a wholly owned subsidiary of Sanofi - Research Funding; Incyte - Consultancy (Includes expert testimony); Cogent Biosciences - Consultancy (Includes expert testimony); Blueprint Medicines Corporation, a wholly owned subsidiary of Sanofi - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony)